Hodgkin Lymphoma

Bio: Hodgkin Lymphoma is an academic researcher. The author has contributed to research in topics: Confidentiality. The author has an hindex of 1, co-authored 1 publications receiving 1631 citations.

SCIENTIFIC PROGRAM (as of May 15, 2023) CONFIDENTIAL

Abstract: Tuesday, June 13, 2023 09:00–17:00 CLOSED WORKSHOP Polivalente Room Lugano Classification: Looking toward the future East Campus USI Organizing Committee: Sally Barrington, London, GB, Bruce D. Cheson, Bethesda, MD, USA, Andrew T. Lister, London, GB, Emanuele Zucca, Bellinzona, CH organized with the support of the American Association for Cancer Research—AACR, the European School of Oncology—ESO and the European Society for Medical Oncology—ESMO (by invitation only) 15:00–17:30 LYMPHOMA RADIOTHERAPY WORKSHOP Cinema Corso Radiation therapy as an immunogenic cell death mechanism in the environment of immunotherapy and adoptive cell therapy Moderators: Bouthaina S. Dabaja, Houston, TX, USA and Joachim Yahalom, New York, NY, USA organized in collaboration with the International Lymphoma Radiation Oncology Group—ILROG (open to all 17‐ICML attendees) 15:05 Past, present and future (hematology perspective) Stephen Ansell, Rochester, MN, USA 15:25 Experimental basis for the contribution of radiation therapy to CAR‐T cell therapy Carl DeSelm, St Louis, MO, USA 15:40 Review of current RT/ CAR‐T programs data Brandon Imber, New York, NY, USA 16:00 Break 16:20 Is there a role for consolidation RT post‐CAR‐T? Patient selection and technical considerations George Mikhaeel, London, UK 16:40 Spectrum of CAR‐T and future directions Bouthaina S. Dabaja, Houston, TX, USA 16:55 Case presentation and discussion Bouthaina S. Dabaja, Houston, TX, USA and Timothy Robinson, New Haven, CT, USA 17:15 Summary and Conclusions Joachim Yahalom, New York, NY, USA Wednesday, June 14, 2023 08:30–09:15 Article nr. “MEET THE PROFESSOR” SESSIONS 5 parallel sessions

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Abstract: Purpose Programmed death 1 is an immune checkpoint that suppresses antitumor immunity. Nivolumab, a fully human immunoglobulin G4 programmed death 1 immune checkpoint inhibitor antibody, was active and generally well tolerated in patients with advanced solid tumors treated in a phase I trial with expansion cohorts. We report overall survival (OS), response durability, and long-term safety in patients with non–small-cell lung cancer (NSCLC) receiving nivolumab in this trial. Patients and Methods Patients (N = 129) with heavily pretreated advanced NSCLC received nivolumab 1, 3, or 10 mg/kg intravenously once every 2 weeks in 8-week cycles for up to 96 weeks. Tumor burden was assessed by RECIST (version 1.0) after each cycle. Results Median OS across doses was 9.9 months; 1-, 2-, and 3-year OS rates were 42%, 24%, and 18%, respectively, across doses and 56%, 42%, and 27%, respectively, at the 3-mg/kg dose (n = 37) chosen for further clinical development. Among 22 patients (17%) with objective responses, esti...